1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Marabelle A, O'Malley DM, Hendifar AE, Ascierto PA, Motola-Kuba D, Penel N, Cassier PA, Bariani G, De Jesus-Acosta A, Doi T, Longo F, Miller WH Jr, Oh DY, Gottfried M, Yao L, Jin F, Gozman A, Maio M.

    Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial

    Nature Cancer . 6(2): 253-258. Nº de citas: 37

    [doi:10.1038/s43018-024-00894-y]

  • Bakirdögen D, Görgülü K, Xin J, Alcalá S, Ruiz-Cañas L, Frank K, Wu N, Diakopoulos KN, Dai C, Öztürk H, Demircioglu D, Peschke K, Ranjan R, Fusco F, Martinez-Useros J, Fernandez-Aceñero MJ, Chhabra NF, López-Gil JC, Ai J, Ruess DA, Kaya-Aksoy E, Steiger K, Schmidt F, Kohlmann L, Berninger A, Schmid RM, Reichert M, Adli M, Lesina M, Sainz B Jr, Algül H.

    c-Rel drives pancreatic cancer metastasis through Fibronectin-Integrin signaling-induced isolation stress resistance and EMT activation.

    Biorxiv : The Preprint Server For Biology . : .

    [doi:10.1101/2025.01.29.635445]

  • Tost J, Ak-Aksoy S, Campa D, Corradi C, Farinella R, Ibáñez-Costa A, Dubrot J, Earl J, Melian EB, Kataki A, Kolnikova G, Madjarov G, Chaushevska M, Strnadel J, Tanic M, Tomas M, Dubovan P, Urbanova M, Buocikova V, Smolkova B.

    Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications

    SEMINARS IN CANCER BIOLOGY . 109: 101-124. Nº de citas: 7

    [doi:10.1016/j.semcancer.2025.01.003]

  • Vaz-Salgado MA, Sepulveda JM, Earl J, Gutierrez J, Ruano Y, Pian H, Cantero D, Segura-Collar B, Gargini R, Hernández-Laín A.

    Oligodendrogliomas, cyclin pathway after the introduction of the molecular 2021 World Health Organization (WHO) criteria

    Brain Communications . 7(5): .

    [doi:10.1093/braincomms/fcaf380]

  • Niedra H, Rogoza O, Saksis R, Peculis R, Halilova A, Gerina A, Vilisova S, Senterjakova N, Pukitis A, Ruz-Caracuel I, Earl J, Kolnikova G, Dubovan P, Tomas M, Makovicky P, Urbanova M, Smolkova B, Koniaris E, Aggelioudaki I, Kataki A, Rovite V.

    Transcriptomic profiling of pancreatic neuroendocrine tumors: dysregulation of WNT, MAPK, PI3K, neddylation pathways and potential non-invasive biomarkers

    PLoS One . 20(6): .

    [doi:10.1371/journal.pone.0325672]

  • Hewitt E, Bouche G, Alencar AC, Bigelsen SJ, Radu R, Stoyanova-Beninska V, Carrato A, Valsecchi F, Soler Cantón A, van der Meer HG, García Bermejo ML, Budillon A, Cardone L, Rooman I, Platteeuw H, Baijet J, Fuchs C.

    Drug Repurposing in Pancreatic Cancer: A Multi-Stakeholder Perspective to Improve Treatment Options for Pancreatic Cancer Patients

    Cancer Management and Research . 17: 429-440. Nº de citas: 2

    [doi:10.2147/CMAR.S483151]

  • Vaz-Salgado MA, Sepulveda JM, Earl J, Gutierrez J, Ruano Y, Pian H, Cantero D, Hernández-Lain A.

    Oligodendrogliomas: findings after classifying the same cohort using pre- and post-World Health Organization (WHO) 2021 criteria

    Brain Communications . 7(4): . Nº de citas: 1

    [doi:10.1093/braincomms/fcaf265]

  • Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D.

    A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6.

    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY . 92(1): 68-77. Nº de citas: 53

    [doi:10.1016/j.jaad.2024.06.108]

  • Candel FJ, Salavert M, Cantón R, Del Pozo JL, Galán-Sánchez F, Navarro D, Rodríguez A, Rodríguez JC, Rodríguez-Aguirregabiria M, Suberviola B, Zaragoza R.

    The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion document.

    CRITICAL CARE . 28(1): 440-440. Nº de citas: 48

    [doi:10.1186/s13054-024-05224-3]

  • Aksoy SA, Earl J, Grahovac J, Karakas D, Lencioni G, Sigirli S, Bijlsma MF.

    Organoids, tissue slices and organotypic cultures: Advancing our understanding of pancreatic ductal adenocarcinoma through in vitro and ex vivo models.

    SEMINARS IN CANCER BIOLOGY . 109: 10-24.

    [doi:10.1016/j.semcancer.2024.12.003]

  • Palencia-Campos A, Ruiz-Cañas L, Abal-Sanisidro M, López-Gil JC, Batres-Ramos S, Saraiva SM, Yagüe B, Navarro D, Alcalá S, Rubiolo JA, Bidan N, Sánchez L, Mura S, Hermann PC, de la Fuente M, Sainz B.

    Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis.

    JOURNAL OF NANOBIOTECHNOLOGY . 22(1): 795-795. Nº de citas: 11

    [doi:10.1186/s12951-024-03010-5]

  • Muñoz Couselo E, Cañueto J, Jerviz Guía V, López López AM, Bermejo Segú JO, García Castaño A, Puig Sardá S, Sanmartín Jiménez O, Soria Rivas A, Gratal P, Pardo MT, Rogado Á, Berrocal Jaime A.

    Recommendations for the management of cutaneous squamous cell carcinoma: a systematic multidisciplinary Delphi consensus approach.

    Clinical & Translational Oncology . : . Nº de citas: 2

    [doi:10.1007/s12094-024-03826-5]

  • Ruz-Caracuel I, Pedraza-Arevalo S, Alonso-Gordoa T, Molina-Cerrillo J, Earl J, Sainz B Jr.

    Everything you ever wanted to know about cancer stem cells in neuroendocrine neoplasms but were afraid to ask.

    Endocrine Oncology (bristol, England) . 4(1): .

    [doi:10.1530/EO-24-0006]

  • Fabra D, Melones-Herrero J, Velazquez-Gutierrez J, Matesanz AI, Aliseda PD, Figueiras S, Aguilar-Rico F, Calés C, Sánchez-Pérez I, Quiroga AG.

    A select thiosemicarbazone copper(II) complex induces apoptosis in gastric cancer and targets cancer stem cells reducing pluripotency markers.

    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY . 280: 116994-116994. Nº de citas: 11

    [doi:10.1016/j.ejmech.2024.116994]

  • Salazar J, Arranz MJ, Martin-Broto J, Bautista F, Martínez-García J, Martínez-Trufero J, Vidal-Insua Y, Echebarria-Barona A, Díaz-Beveridge R, Valverde C, Luna P, Vaz-Salgado MA, Blay P, Álvarez R, Sebio A.

    Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol.

    Pharmaceutics . 16(12): .

    [doi:10.3390/pharmaceutics16121585]

  • Vaz-Salgado MA, Albarran V, Pozas J, Ferreiro R, Pachón V, Longo F, Rodriguez M, Barreto E, Earl J.

    Single nucleotide polymorphisms: impact on susceptibility to chemotherapy in patients with colorectal cancer.

    Future Science OA . 10(1): 2428077-2428077. Nº de citas: 1

    [doi:10.1080/20565623.2024.2428077]

  • Sotoca Rubio P, Barrill Corpa AM, Alia Navarro V, Pérez de Aguado Rodríguez P, Moreno Doval J, Calvo Pérez JC, Guerrero Serrano P, García Merino C, García de Quevedo Suero C, Fernández-Fradejas J, Serrano Domingo JJ, Martínez Delfrade Í, Morón García BI, Ferreiro Monteagudo MR, De Frutos González B.

    Efficacy and safety of regorafenib for the treatment of metastatic colorectal cancer in routine clinical practice: results from a Spanish hospital.

    Frontiers in Oncology . 14: 1446945-1446945.

    [doi:10.3389/fonc.2024.1446945]

  • Llach J, Luzko I, Earl J, Barreto E, Rodríguez-Garrote M, Lleixà M, Herrera-Pariente C, Fernández G, Munoz J, Bonjoch L, Saurí T, Ausania F, Ocaña T, Moreno L, Grau E, Oriola J, Alvarez-Mora MI, Herreros-Villanueva M, Castellví-Bel S, Balaguer F, Bujanda L, Moreira L.

    Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study.

    Cancers . 16(22): . Nº de citas: 2

    [doi:10.3390/cancers16223779]